Comparison of Triggering Final Oocyte Maturation with Follicle Stimulating Hormone Plus Human Chorionic Gonadotropin, versus Human Chorionic Gonadotropin Alonein Normoresponder Women Undergoing Intracytoplasmic Sperm Injection: A Randomized Clinical Trial

被引:0
作者
Ansaripour, Soheila [1 ]
Tamizi, Nayereh [1 ,3 ]
Sadeghi, Mohammad Reza [2 ]
Mohammad-Akbari, Azam [1 ]
机构
[1] ACECR, Avicenna Res Inst, Nanobiotechnol Res Ctr, Tehran, Iran
[2] ACECR, Avicenna Res Inst, Reprod Biotechnol Res Ctr, Tehran, Iran
[3] ACECR, Avicenna Res Inst, Nanobiotechnol Res Ctr, POB 1983969412, Tehran, Iran
关键词
Fertilization; Follicle Stimulating Hormone; Human Chorionic Gonadotropin; Pregnancy Rate; Triggering Oocyte Maturation; IN-VITRO FERTILIZATION; GNRH AGONIST; DUAL TRIGGER; HCG; COMBINATION; IMPROVES; CYCLES; TIME;
D O I
10.22074/IJFS.2021.532258.1141
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Few studies have so far been done about the role of follicle stimulating hormone (FSH) in final oocyte maturation. However, none of these studies have been performed solely on normoresponder patients. This study aimed to determine whether oocyte maturation, as well as fertilization and pregnancy rates, could be improved in normore-sponder women with concomitant FSH and human chorionic gonadotropin (hCG) trigger compared to those with the hCG trigger alone.Materials and Methods: In this prospective randomized clinical trial, 117 normoresponder women, aged 19-40 years who were candidates for the gonadotropin-releasing hormone (GnRH) antagonist protocol at Avicenna Infertility treatment Center, were enrolled and claasified in two groups. Final oocyte maturation was triggered using 10000 IU of hCG plus 450 IU of FSH in the first group (59 subjects) and 10000 IU of hCG alone in the second group (58 subjects). The primary outcome was clinical pregnancy rate.Results: Mean age of the patients was 33.21 +/- 4.41 years. There was no difference in clinical pregnancy among the two groups (30.9% vs. 25.5%, P=0.525). There was no statistically significant difference in fertilization rate (80.0% vs. 74.1%, P=0.106), implantation rates (18.9% vs. 16.7%, P=0.352), and chemical pregnancy rates (38.2% vs. 32.7%, P=0.550). Oocyte maturation rate (84.2% vs. 73.6%, P<0.001), 2 pronuclei (2PNs) (6.53 +/- 2.54 vs. 5.36 +/- 2.85, P=0.021) and total embryos (5.85 +/- 2.43 vs. 4.91 +/- 2.58, P=0.046) were significantly higher in the first group.Conclusion: Adding FSH to hCG for oocyte triggering, significantly improved oocyte maturation rates and total em-bryos. While there was no significant difference in the clinical and chemical pregnancy rates, between these two groups (registration number: IRCT20190108042285N1).
引用
收藏
页码:162 / 166
页数:5
相关论文
共 19 条
[11]   A 'FOLLICLE-STIMULATING HORMONE BOOST' ADMINISTERED AT THE TIME OF HUMAN CHORIONIC GONADOTROPIN TRIGGER DOES NOT AFFECT IVF CYCLE OUTCOMES. [J].
Juneau, C. R. ;
Morin, S. J. ;
Franasiak, J. M. ;
Landis, J. N. ;
Molinaro, T. A. ;
Scott, R. T. .
FERTILITY AND STERILITY, 2016, 106 (03) :E189-E190
[12]   Combined ovulation triggering with GnRH agonist and hCG in IVF patients [J].
Kasum, Miro ;
Kurdija, Kristijan ;
Oreskovic, Slavko ;
Cehic, Ermin ;
Pavicic-Baldani, Dinka ;
Skrgatic, Lana .
GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (11) :861-865
[13]   Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial [J].
Lamb, Julie D. ;
Shen, Shehua ;
McCulloch, Charles ;
Jalalian, Liza ;
Cedars, Marcelle I. ;
Rosen, Mitchell P. .
FERTILITY AND STERILITY, 2011, 95 (05) :1655-1660
[14]   Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles [J].
Lin, Ming-Huei ;
Wu, Frank Shao-Ying ;
Lee, Robert Kuo-Kuang ;
Li, Sheng-Hsiang ;
Lin, Shyr-Yeu ;
Hwu, Yuh-Ming .
FERTILITY AND STERILITY, 2013, 100 (05) :1296-1302
[15]   A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study [J].
Papanikolaou, Evangelos G. ;
Verpoest, Willem ;
Fatemi, Human ;
Tarlatzis, Basil ;
Devroey, Paul ;
Tournaye, Herman .
FERTILITY AND STERILITY, 2011, 95 (03) :1174-1177
[16]   Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study [J].
Qiu, Qi ;
Huang, Jia ;
Li, Yu ;
Chen, Xiaoli ;
Lin, Haiyan ;
Li, Lin ;
Yang, Dongzi ;
Wang, Wenjun ;
Zhang, Qingxue .
HUMAN REPRODUCTION, 2020, 35 (06) :1411-1420
[17]   The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART [J].
Vlaisavljevic, Veljko ;
Apter, Susanna ;
Capalbo, Antonio ;
D'Angelo, Arianna ;
Gianaroli, Luca ;
Griesinger, Georg ;
Kolibianakis, Efstratios M. ;
Lainas, George ;
Mardesic, Tonko ;
Motrenko, Tatjana ;
Pelkonen, Sari ;
Romualdi, Daniela ;
Vermeulen, Nathalie ;
Tilleman, Kelly .
HUMAN REPRODUCTION OPEN, 2021, 2021 (03)
[18]  
Yding Andersen C, 2002, Reprod Biomed Online, V5, P232
[19]   Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles [J].
Youssef, Mohamed A. F. M. ;
Van der Veen, Fulco ;
Al-Inany, Hesham G. ;
Griesinger, Georg ;
Mochtar, Monique H. ;
Aboulfoutouh, Ismail ;
Khattab, Sherif M. ;
van Wely, Madelon .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (01)